Psychedelic Bulletin #102 – Our Analysis of MindMed’s LSD for Anxiety Results; Mail-Order Ketamine May Come Under Scrutiny; Our Notes from PSYCH Symposium

• Post published:May 16, 2022
• Post category:Psychedelic Bulletin

Psychedelic Research Bulletin: April 2022

• Post published:May 12, 2022
• Post category:Psychedelics Research Review

Psychedelic Bulletin #101 – Psychedelic R&D in the UK; COMPASS Study Points to Psilocybin for Anorexia

• Post published:May 6, 2022
• Post category:Psychedelic Bulletin

Psilocybin Alpha is now Psychedelic Alpha

• Post published:April 28, 2022
• Post category:Announcements

Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine Therapy; Psychedelics Research Review

• Post published:April 25, 2022
• Post category:Psychedelic Bulletin

Psychedelic Research Bulletin: March 2022

• Post published:April 24, 2022
• Post category:Psychedelics Research Review

MYND Life Sciences Announces $3.5 Million Share Offering

• Post published:April 21, 2022
• Post category:Press Release

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

• Post published:April 21, 2022
• Post category:Press Release

COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers

• Post published:April 20, 2022
• Post category:Press Release

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds

• Post published:April 19, 2022
• Post category:Press Release